Protein arginine methyltransferase 5 (PRMT5) represents a novel epigenetic anti-tumour target with significant clinical potential, and has attracted considerable interest from the academic research community and the pharmaceutical industry.
This review provides key updates on the innovation and application of chemical approaches and tools for studying functions of PRMTs and arginine methylation in regulating biology and disease.
An enzyme-responsive hydrogel to co-deliver cisplatin and shRNA, targeting NED-driven chemoresistance in NSCLC.
SAR and docking analysis indicate important structural determinants and binding interactions that promote Selective and Dual PRMT1 and PRMT4 inhibition, making them potentially useful as epigenetic targets in various cancer treatments.
The review focuses on small molecules that modulate RNA splicing by interacting with a variety of targets, and in the context of disease treatment.